New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
14:58 EDTAETEarnings Preview: Aetna shares up 16% since last earnings report
Aetna (AET) is scheduled to report second quarter earnings before the market open on Tuesday, July 29, with a conference call scheduled for 8:30 am ET. Aetna operates as a diversified health care benefits company in the United States. EXPECTATIONS: Analysts are looking for earnings per share of $1.60 on revenue of $13.99B, according to First Call. The consensus range for EPS is $1.50-$1.77 on revenue of $13.23B-$14.51B. LAST QUARTER: On April 24, Aetna reported first quarter EPS of $1.98 against estimates of $1.56 on revenue of $13.99B against estimates of $13.72B. Aetna said operating revenues for Q1 were $14B compared with $9.5B in Q1 of the previous year. The 47% increase in operating revenues was primarily the result of higher Health Care premiums from the acquisition of Coventry and pricing actions designed to recover Health Care Reform mandated fees and taxes as well as membership growth in our underlying Health Care businesses. STREET RESEARCH: On June 10, Credit Suisse said meetings with Aetna management were upbeat and reinforced its positive view. Management noted cost trends remained muted and were optimistic on Community Health integration, public/private exchanges and M&A. Shares are Outperform rated with a price target of $90. PRICE ACTION: Shares of Aetna are up more than 16% since its last earnings report. Shares are 1.7% higher today in afternoon trading ahead of tomorrow's earnings report.
News For AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:44 EDTAETStocks end week lower as GDP revision closes May on down note
Subscribe for More Information
16:19 EDTAETOn The Fly: Top stock stories for Friday
Stocks on Wall Street began the final trading day of May with slight losses. The averages began to pick up downside momentum after revised GDP numbers confirmed expectations that the economy shrank in the first quarter of the year. The Wall Street adage of “sell in May, then go away” appeared to be taking hold as the S&P broke a support level and took the other averages with it. Investors are now concerned about a June swoon, as it is historically one of the worst performing months of the year. ECONOMIC EVENTS: In the U.S., the second estimate of gross domestic product showed it shrank at a 0.7% seasonally adjusted annual rate in the first quarter. This was down from the previous estimate that output grew 0.2% from January through March, but better than the revision to a 1% decline that had been forecast by analysts. The Chicago PMI unexpectedly dropped 6.1 points to 46.2 in May, versus expectations for it to have risen to a reading of 53. The University of Michigan's consumer sentiment reading came in with a 90.7 reading for the final May print, which was up from the preliminary 88.6 reading for the month but down from April's 95.9 figure. COMPANY NEWS: Shares of Humana (HUM) jumped $36.24, or 20.31%, to $214.65 after The Wall Street Journal said the company has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of takeover interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders for Humana. Bloomberg then said Humana's sale exploration came after Cigna made a takeover approach. Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. MAJOR MOVERS: Among the notable gainers was Heron Therapeutics (HRTX), which gained $7.41, or 60%, to $19.76 after the company reported positive top-line data from a Phase 3 marketing study looking at Sustol as part of a 3-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents. Also higher was Altera (ALTR), which advanced $1.88, or 4%, to $48.85 after reports from The New York Post and Financial Times claimed the company is near a deal to be acquired by chipmaking giant Intel (INTC) for up to $54 per share. Reuters, meanwhile, revised its prior report to indicate the potential price of the deal could be close to $16B. Among the noteworthy losers was Abercrombie & Fitch (ANF), which fell $1.63, or 7.38%, to $20.47 after Janney Capital downgraded the stock to Sell from Hold and warned the company's comparative sales may continue to drop year-over-year as it changes nearly every aspect of its business. Also lower were shares of Bristol-Myers Squibb (BMY), which dropped $4.55, or 6.58%, to $64.60 after the company reported data from a Phase III study evaluating Opdivo in previously-treated patients with advanced, non-squamous non-small cell lung cancer. Biotech analyst Mark Schoenebaum reportedly said Bristol-Myers' data from its Checkmate 057 study opens the door for lung cancer competition from Merck (MRK) and Roche (RHHBY), according to TheStreet's Adam Feuerstein. INDEXES: The Dow dropped 115.44, or 0.64%, to 18,010.68, the Nasdaq lost 27.95, or 0.55%, to 5,070.03, and the S&P 500 fell 13.40, or 0.63%, to 0.63.
15:15 EDTAETAetna options active following report Humana considering possible sale
Subscribe for More Information
15:11 EDTAETAmerisourceBergen reverses after report of potential Humana sale
Subscribe for More Information
15:00 EDTAETExpress Scripts falling, Anthem rising after report of possible Humana sale
Subscribe for More Information
13:50 EDTAETHumana surges after report says sale being explored
Shares of health insurer Humana (HUM) are surging in afternoon trading after a report claimed the company is exploring a potential sale after receiving indications of takeover interest. WHAT'S NEW: The Wall Street Journal, citing sources, reported that Humana has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders. WHAT'S NOTABLE: After meeting with Aetna's (AET) management, Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. The next day, Sterne Agee analyst Brian Wright said Humana was unlikely to be acquired with its stock where it has recently been trading. Wright, who added that speculation about a takeover is "wishful thinking," downgraded Humana shares to Underperform, the firm's sell equivalent rating, and cut his price target on the stock to $150 from $165. OTHERS TO WATCH: Other publicly traded companies in the space include Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). PRICE ACTION: In afternoon trading, Humana jumped 17.33% to $209.33, Aetna rose 2.1% to $118.84 and Cigna gained 4.45% to $141.91.
13:17 EDTAETHumana considering sale after receiving takeover interest, WSJ reports
Humana (HUM) is working with advisers at Goldman Sachs (GS) to consider a potential sale after receiving indications of takeover interest, reported The Wall Street Journal, citing people familiar with the matter. Some of the people said Aetna (AET) and Cigna (CI) are among possible bidders for Humana, the report added. In afternoon trading, Humana jumped 5% before being halted for volatility, while Aetna rose nearly 1% and Cigna gained about 2%. Reference Link
May 26, 2015
16:42 EDTAETAetna Chief Accounting Officer to depart July 3, AES's Sharon Virag to succeed
Subscribe for More Information
May 20, 2015
07:42 EDTAETAetna removed from US Focus List at Credit Suisse
Subscribe for More Information
May 19, 2015
12:04 EDTAETAnthem CFO says 'good time' for 'meaningful' acquisition, Reuters reports
Subscribe for More Information
May 18, 2015
09:33 EDTAETAetna repeats FY15 operating EPS view $7.20-$7.40, consensus $7.38
Subscribe for More Information
May 15, 2015
16:51 EDTAETGreenlight Capital gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use